Overview

Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema

Status:
Unknown status
Trial end date:
2017-11-01
Target enrollment:
0
Participant gender:
All
Summary
Multicenter randomized trials have demonstrated the safety and efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of diabetic macular edema. The results are generally good in the short term, with approximately 75% of patients maintaining or improving vision after initiation of treatment. Despite this favorable outcome, the observation of persistent fluid is not infrequent during treatment, even in patients undergoing monthly treatment sessions. Persistent fluid was observed on optical coherence tomography (OCT) in 70.9% of patients receiving bevacizumab monthly and in 79% of those receiving bevacizumab as needed at the end of the first year in the Comparison of diabetic macular edema. Treatment Trials. It is possible that resolution of this fluid, especially when it is centrally located (i.e., foveal), might result in better visual outcomes. A drug with higher VEGF-binding affinity may help patients with persistent fluid despite treatment with bevacizumab. Aflibercept is a new intravitreal VEGF antagonist approved on 28 November 2014 by the Health Canada for the treatment of diabetic macular edema. In contrast to the antibody-based VEGF binding strategy used by bevacizumab, aflibercept incorporates the second binding domain of the VEGFR-1 receptor and the third domain of the VEGFR-2 receptor. By fusing these extracellular protein sequences to the Fc segment of a human IgG backbone, developers have created a chimeric protein with a very high VEGF binding affinity. Aflibercept binds all isomers of the VEGF-A family like bevacizumab, but it also binds VEGF-B and placental growth factors 1 and 2,1,2 which have been both implicated in the pathogenesis of diabetic retinopathy and of age-related macular degeneration. In addition, because of the increased trough binding activity and the stronger binding affinity, aflibercept should be efficacious in neutralizing VEGF more effectively and for longer duration.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Collaborator:
Bayer
Treatments:
Aflibercept
Bevacizumab
Criteria
Inclusion Criteria:

- Eyes to be included in the series must have had at least six consecutive monthly
intravitreal injections of bevacizumab for the treatment of diabetic macular edema and
presented tomographic signals suggestive of foveal fluid on spectral-domain optical
coherence tomography (SD-OCT) 4 weeks after the last treatment session. The interval
between each of the last 3 consecutive bevacizumab treatments and the interval between
the last bevacizumab and the SD-OCT imaging not exceeding 37 days.

- Persistent foveal fluid is defined as the observation of hypo-reflective spaces on OCT
at the fovea (fovea centralis), which measures approximately 1.5 mm (1500 μm) or one
disc diameter in size centered at the macular umbo. Tomographic changes will be
measured by SD-OCT using the macular thickness maps.

- BCVA must be better than 20/800. Only 1 eye from each patient will be included in the
study. If both eyes are affected, the better seeing eye will be included, since no
previous meaningful difference was found in patients with 20/40 or better when treated
with bevacizumab or aflibercept.3

Exclusion Criteria:

- An ocular media opacity that might interfere with visual acuity, assessment of
toxicity, or photographic fundus documentation of the macular area.

- A history of vitrectomy.

- Known coagulation abnormalities, stroke, or recurrent use of anticoagulative
medication other than aspirin.

- Pregnancy, or planning for pregnancy during the study time frame or the following 3
months.

- Patients actively undergoing other ocular treatment options such as topical
nonsteroidal anti-inflammatory drugs NSAIDs, topical steroids, or intravitreal
steroids injections will be excluded from the study.